Limited diagnostic resources, such as EPO level tests, can result in late or misdiagnosis and increased health care costs. The average cost of hospitalization for a TE was $4000-9000 higher than for generally medically ill patients. Investigators noted improved spleen size and blood parameters in addition to improvement in PV symptoms. Rusfertide improved response maintenance and reduced the need for therapeutic phlebotomy.